Lexeo Therapeutics, Inc. LXEO

Full chart Compare
Set alert

Price alert · LXEO

All alert types
3.11 USD +0.05 (+1.63%)

At closeNov 3, 2026, 4:01 PM EST

3.11 0.00 0.00%

After hours · Nov 3, 4:01 PM ET

3.01 Day range 3.30
2.55 52-week range 10.99
YTD
-68.68%
1 year
-65.60%

Analyst view

Price target (mean) 22.29 +616.6% upside
Target (low)
16.00
Target (mean)
22.29
Target (high)
28.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
  • Strong buy3
  • Buy4
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 7
  • 1 month ago 6
  • 2 months ago 7

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

LXEO analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.77664-0.90 – -0.609860.000.0%00.0%6
Next quarter-0.795-0.93 – -0.53-0.77-3.3%00.0%4
Current year-2.75-3.01 – -2.55-12.30+77.6%00.0%6
Next year-3.01-3.84 – -1.79-2.75-9.4%750.00K0.0%6

Upgrades and downgrades

The latest rating changes

LXEO analyst upgrades and downgrades
DateFirmActionFromTo
Nov 14, 2024HC Wainwright & Co.MaintainedBuyBuy
Nov 13, 2024Chardan CapitalMaintainedBuyBuy
Nov 13, 2024Leerink PartnersMaintainedOutperformOutperform
Oct 31, 2024HC Wainwright & Co.ReiteratedBuyBuy
Oct 30, 2024Chardan CapitalMaintainedBuyBuy
Oct 25, 2024Chardan CapitalMaintainedBuyBuy
Aug 14, 2024Chardan CapitalMaintainedBuyBuy
Aug 13, 2024HC Wainwright & Co.MaintainedBuyBuy
Aug 13, 2024RBC CapitalReiteratedOutperformOutperform
Jul 16, 2024HC Wainwright & Co.ReiteratedBuyBuy
Jul 15, 2024Chardan CapitalMaintainedBuyBuy
Jun 13, 2024BairdInitiated—Outperform
Jun 6, 2024HC Wainwright & Co.Initiated—Buy
Mar 12, 2024RBC CapitalMaintainedOutperformOutperform
Nov 28, 2023Chardan CapitalInitiated—Buy
Nov 28, 2023Leerink PartnersInitiated—Outperform
Nov 28, 2023RBC CapitalInitiated—Outperform
Nov 28, 2023StifelInitiated—Buy
Nov 28, 2023JP MorganInitiated—Overweight